Full Coverage

BioAlliance Pharma acquired European rights for Ondansetron OS

                   
tmcnet.com
May 20, 2008
        
Story Timeline:  197 days

Via Acquire Media NewsEdge) BioAlliance acquired European rights for Ondansetron oral spray to complement its franchise in cancer supportive care from NovaDel Pharma Inc. Paris, May 20, 2008 - BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer... [read full story]                    

Add Comment
Latest article on this story:

BioAlliance Acquired European Rights For Ondansetron Oral Spray To Complement Its Franchise In...

 pharmiweb.co.uk May 22, 2008
First article on this story:

BioAlliance Acquired European Rights for Ondansetron Oral Spray to Complement its Franchise in...

 wallstreet-online.de May 20, 2008
Selected publications with coverage of this story:
marketwatch.com marketwire.com medicalnewstoday.com yahoo.com finanzen.net earthtimes.org tmcnet.com pharmiweb.co.uk wallstreet-online.de finanznachrichten.de
RELATED
Found 13 documents:
                   

BioAlliance Acquired European Rights For Ondansetron Oral Spray To Complement Its Franchise In...

medicalnewstoday.com
May 21, 2008
        

BioAlliance Pharma SA (Paris:BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced that it has acquired the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD).

                   

NovaDel Gets Potential $27M in Deal for Anti-Nausea Drug

tmcnet.com
May 20, 2008
        

Flemington, N.J.-based NovaDel plans to use the money to "reinitiate a lot of our clinical development" that had been curtailed due to a lack of money, Mike Spicer, chief financial officer, told BioWorld Today. Under the deal, Paris-based BioAlliance will be responsible for European regulatory...

                   

NovaDel Announces European License Agreement for Ondansetron Oral Spray (Business Wire)

yahoo.com
May 20, 2008
        

FLEMINGTON, N.J.----NovaDel Pharma Inc. , a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today entered into a collaboration agreement with BioAlliance Pharma SA for the development and commercialization of NovaDel's ondansetron oral...

BioAlliance acquires Europe rights to NovaDel nausea drug (at MarketWatch)

yahoo.com
May 20, 2008
        

TEL AVIV (MarketWatch) -- BioAlliance Pharma SA, the Paris drugmaker focused on infections arising from cancer and HIV, said it acquired the rights to market ondansetron oral spray in Europe from NovaDel Pharma Inc., the Flemington, N.J., drugmaker. The spray prevents nausea and vomiting in...

BioAlliance acquires Europe rights to NovaDel nausea drug

marketwatch.com
May 20, 2008
        

TEL AVIV (MarketWatch) -- BioAlliance Pharma SA, the Paris drugmaker focused on infections arising from cancer and HIV, said it acquired the rights to market ondansetron oral spray in Europe from NovaDel Pharma Inc., the Flemington, N.J., drugmaker. The spray prevents nausea and vomiting in...

BioAlliance acquires European rights to ondansetron OS from Novadel

finanznachrichten.de
May 20, 2008
        

PARIS (Thomson Financial) - BioAlliance Pharma said it has acquired the European commercial rights to ondansetron Oral Spray (OS), which is being developed by NovaDel Pharma Inc . BioAlliance said it has paid NovaDel a licence fee of $3 million, in addition to which NovaDel is eligible for...

                   

BioAlliance Acquired European Rights for Ondansetron Oral Spray to Complement its Franchise in...

finanznachrichten.de
May 20, 2008
        

Regulatory News: BioAlliance Pharma SA (Paris:BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has acquired the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD)....

                   

BioAlliance Acquired European Rights for Ondansetron Oral Spray to Complement its Franchise in...

finanzen.net
May 20, 2008
        

Regulatory News: BioAlliance Pharma SA (Paris:BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has acquired the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD)....

                   

BioAlliance Pharma acquired European rights for Ondansetron OS (Marketwire)

yahoo.com
May 20, 2008
        

PARIS--(MARKET WIRE)--May 20, 2008 -- BioAlliance acquired European rights for Ondansetron oral spray to complement its franchise in cancer supportive care from NovaDel Pharma Inc. Paris, May 20, 2008 - BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections...

                   

BioAlliance Pharma acquired European rights for Ondansetron OS

earthtimes.org
May 20, 2008
        

PARIS -- BioAlliance acquired European rights for Ondansetron oral spray to complement its franchise in cancer supportive care from NovaDel Pharma Inc. Paris, May 20, 2008 - BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today...

1 2 next